Wien, 28 - Repository of the LBI-HTA - Ludwig Boltzmann Gesellschaft

Tabelle 5-1: Evidence profile: efficacy and safety of radiofrequency ablation in renal cell carcinoma
No of studies/patients
Design Limitations Consistency
of results
1/208 case series serious limitations
2/339 case series serious limitations
1/20 case series serious limitations
2/151 case series serious limitations
1/131 case series serious limitations
Radiofrequenzablation bei Tumoren des Urogenitaltrakts
(Nierenzellkarzinom, Prostatakarzinom, Leiomyome des Uterus)
Directness Effect size Other modifying
factors*
34 LBI-HTA | 2012
Efficacy
Outcome: overall survival rate
Quality of
evidence
only one trial direct 85% at 5 yrs sparse data very low
no important direct
Outcome: recurrence rate
10% at 1 month
inconsistency
20 lack of precise very low
Outcome: quality of life
data, sparse data
only one trial direct score: SF-36
lack of precise very low
no significant improvement at 6 months compared to baseline
Safety
Outcome: overall complications (major)
data; sparse data
no important
inconsistency
direct 0% at n/a
Outcome: overall complications (minor)
sparse data very low
21
only one trial direct 17-24% at n/a
Outcome: mortality (procedure-related)
no evidence
lack of precise
data; sparse data
very low
* low incidence, lack of precise data, sparse data, strong or very strong association, high risk of publication bias, dose-efficacy gradient, residual confounding plausible
20 refers to 41 endophytic tumors in one case series only; in the second case-series recurrenct RCC occured in 9 pts with biopsy-proven RCC at ≤36 months of follow-up, however, the
total number of pts with biopsy-proven RCC remains unclear.
21 including haematuria, urinary retention, lower extremity paraesthesia, flank bruising